These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Eye Cancer (Malignant Neoplasm of Eyeball)
DBQ Overview
Interview + Physical- Form Name
- Eye_Conditions
- Form Code
- Eye_Conditions
- Page Count
- 14
- Examiner Type
- Ophthalmologist or Optometrist
- Estimated Duration
- 30-45 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To evaluate the current severity of a malignant neoplasm of the eyeball, including tumor status, treatment history, residual functional impairment, and any complications affecting vision or surrounding ocular structures. The examiner will also assess whether the cancer is active, in remission, or cured, and document all associated residual conditions for rating purposes under DC 6014.
What the examiner evaluates:
- Current cancer status: active, in treatment, in remission, or resolved
- Type, location, and laterality of the ocular malignancy (e.g., uveal melanoma, retinoblastoma, conjunctival carcinoma)
- Treatment history including surgery (enucleation, exenteration, plaque brachytherapy), radiation therapy, chemotherapy, and immunotherapy
- Residual visual acuity in both eyes - corrected and uncorrected, distance and near
- Visual field defects including scotomas, hemianopsia, or concentric constriction
- Intraocular pressure (IOP) and any secondary glaucoma
- Presence of an ocular prosthesis or anophthalmic socket complications
- Retinal involvement, detachment, or secondary maculopathy from treatment
- Optic nerve involvement or neuropathy
- Eyelid changes including ptosis, loss of eyelashes or eyebrows, entropion, or ectropion
- Diplopia or extraocular muscle dysfunction
- Photophobia or glare sensitivity
- Pain - ocular, periorbital, or orbital
- Incapacitating episodes resulting from eye conditions
- Impact on daily functioning, employment, and activities of daily living
The examination will typically include a slit-lamp biomicroscopy assessment, visual acuity testing, visual field evaluation (perimetry), tonometry for IOP measurement, dilated fundus examination if applicable, and a thorough review of your oncology and ophthalmology treatment records. Bring all relevant records, pathology reports, and imaging results to the exam.
Typical duration: 30-45 minutes
Best-Corrected Visual Acuity (BCVA) - Distance and Near
The sharpest vision achievable with the best corrective lenses in each eye, measured separately. This is the primary driver of the VA combined visual acuity rating table and directly determines the compensation percentage under 38 CFR 4.79 Tables I-VI.
What to expect:
You will read a Snellen eye chart (letters or numbers at 20 feet for distance; near card for near vision) first without correction, then with your best glasses or contact lenses. Each eye is tested independently. The examiner documents results such as 20/20, 20/200, or counting fingers (CF), hand motion (HM), or light perception (LP).
Key thresholds:
- 20/200 or worse in both eyes — Combined table rating approaches maximum; may qualify for SMC under 38 USC 1114
- 20/100 in one eye — Significant combined rating depending on other eye acuity
- 20/40 or better — Lower rating range; ensure near vision is also tested as it may differ
- No light perception (NLP) in affected eye — Treated as loss of use of the eye; rated at 20/200 for VA purposes; may qualify for SMC
Tips:
- Do NOT memorize the eye chart before the exam - this produces inaccurate results that may actually harm your claim
- If you wear glasses or contacts, bring them to the exam; test both with and without correction
- Tell the examiner if your vision fluctuates significantly day to day and describe your worst-functioning days
- If you have an ocular prosthesis or enucleated eye, clearly state that no vision is present in that socket
- Near vision may be worse than distance vision and should be separately documented - remind the examiner if they skip this
Pain considerations: Ocular pain or discomfort from dry eye, socket irritation, or radiation-related changes may impair your ability to cooperate with acuity testing. Inform the examiner of any pain that prevents you from keeping your eye open or focusing during testing.
Visual Field Testing (Perimetry)
The extent and integrity of your peripheral and central vision, measured in degrees from fixation in multiple meridians. Critical for detecting scotomas, field losses from retinal or optic nerve damage, or hemianopsia caused by tumor involvement or treatment sequelae.
What to expect:
The examiner may use Goldmann perimetry (manual, kinetic), automated perimetry (Humphrey), or confrontation visual fields. You will fixate on a central target and indicate when you see a light or object in your peripheral vision. The examiner documents the extent of your visual field in degrees for each meridian of each eye.
Key thresholds:
- Visual field of 5 degrees or less (near total constriction) — Highest rating tier; treated similar to visual acuity of 5/200
- Visual field 6-20 degrees (severe concentric constriction) — High combined rating; significantly impairs function
- Scotoma affecting 1/4 or more of visual field — Rated at appropriate reduced acuity level per 38 CFR 4.79 rules
- Homonymous or bitemporal hemianopsia — Rated at 20/200 for the affected field half in each eye
Tips:
- Describe any blind spots, dark areas, or missing portions of your vision that you experience in daily life
- If you experience worse visual field loss at certain times of day or under fatigue, communicate this to the examiner
- Goldmann perimetry is generally preferred for VA rating purposes - ask if the examiner plans to use it
- Central scotomas (affecting the center of vision) are particularly functionally significant; describe difficulty reading, recognizing faces, or seeing fine detail
Pain considerations: Radiation-induced dry eye or photophobia may make prolonged perimetry testing uncomfortable. Inform the examiner if pain or tearing is interfering with your ability to maintain fixation during testing.
Intraocular Pressure (IOP) Measurement
The fluid pressure inside the eye, normally 10-21 mmHg. Elevated IOP indicates secondary glaucoma, which is a ratable separate condition that can develop after radiation therapy, neovascularization, or tumor infiltration of the trabecular meshwork.
What to expect:
The examiner will instill numbing eye drops and apply a Goldmann applanation tonometer to the front of your eye, or use a non-contact air-puff tonometer. Each eye is measured. Normal is under 21 mmHg; glaucomatous damage typically occurs at sustained pressures above 21 mmHg.
Key thresholds:
- IOP > 21 mmHg sustained — Supports secondary glaucoma diagnosis, which is separately ratable
- IOP > 30 mmHg despite maximal therapy — Severe glaucoma; may affect visual acuity and field ratings significantly
Tips:
- Tell the examiner if you are currently using glaucoma eye drops or have been told you have elevated eye pressure as a treatment side effect
- If you are between glaucoma medication doses at the time of exam, pressure may be temporarily higher - document your medication schedule
- Secondary glaucoma after radiation or surgery for eye cancer should be separately claimed as a secondary condition
Pain considerations: If you experience acute eye pain, halos around lights, or blurred vision with headache, these may indicate acute angle-closure or pressure spikes - report these symptoms clearly.
Slit-Lamp Biomicroscopy
A magnified examination of the anterior and posterior segments of the eye, including cornea, lens, iris, vitreous, and retina. Used to evaluate treatment effects, tumor recurrence, radiation-induced cataracts, corneal damage, or posterior segment complications.
What to expect:
You will rest your chin on a support while the examiner shines a narrow beam of light into your eye using a microscope. This may include fundus examination with a special lens after pupil dilation. The exam takes 10-15 minutes.
Key thresholds:
- Radiation cataract present — Separately ratable as a lens condition; may require cataract surgery notation
- Retinal detachment or maculopathy noted — Affects visual acuity rating and should be separately documented
- Tumor recurrence or active disease noted — Triggers 100% rating during active malignancy period under DC 6014
Tips:
- If you have had pupil dilation before, inform the examiner and arrange transportation as you may not be able to drive afterward
- Describe any symptoms of radiation cataract - hazy, foggy, or blurred vision that worsens over time post-treatment
- Optic nerve pallor or atrophy from radiation should be specifically noted as it separately affects visual function
Pain considerations: If the slit-lamp light causes significant photophobia or pain, tell the examiner immediately - this is a ratable symptom and should be documented.
Extraocular Motility and Diplopia Assessment
The alignment and full range of motion of both eyes together. Malignant tumors in or around the orbit, or surgical and radiation complications, can cause restrictive strabismus, cranial nerve palsies, or diplopia (double vision).
What to expect:
The examiner will ask you to follow a target (light or pen) in multiple directions (up, down, left, right, obliques) and will note whether both eyes track together and whether you report diplopia in any gaze position.
Key thresholds:
- Constant diplopia in primary (straight-ahead) gaze — Significantly higher rating; constant diplopia is severely disabling
- Diplopia in any field of gaze — Ratable; frequency and gaze positions are critical to document
- Complete loss of ocular motility (ophthalmoplegia) — Rated under nerve paralysis codes; may combine with visual ratings
Tips:
- If you use a prism in your glasses for diplopia, bring them and mention this to the examiner
- Describe whether diplopia is horizontal, vertical, or oblique and in which direction of gaze it occurs
- Occasional vs. constant diplopia is a significant distinction - describe the frequency accurately on your worst typical days
Pain considerations: Diplopia with eye movement may be accompanied by headache or periorbital pain - document these associated symptoms.
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 100% | Active malignant neoplasm of the eyeball, OR surgery more extensive than enucleation performed (e.g., orbital exenteration), rated as 100% during the period of active treatment and for a minimum of 6 months following the completion of treatment. After the treatment period, the condition is rated based on residual conditions under the appropriate diagnostic codes. |
CFR: Under DC 6014, malignant neoplasm of the eyeball is rated 100% while active and for 6 months following completion of treatment. Post-treatment residuals are then rated under the applicable diagnostic codes for visual impairment, field defects, or other residual conditions. A mandatory VA examination is required no later than the end of the 6-month period after completion of treatment. |
| 60% | Post-treatment residual rating based on visual acuity in the remaining eye(s). If the affected eye has been enucleated (removed), the remaining eye's best-corrected visual acuity combined with any visual field defects determines the rating under Tables I-VI of 38 CFR 4.79. Visual acuity of 20/200 or worse in the remaining eye after enucleation of the other eye typically yields a 60% or higher combined rating. |
CFR: Under Tables I-VI, various combinations of visual acuity in both eyes yield specific combined ratings. After enucleation of one eye, the rating is determined by the remaining eye's acuity. Visual acuity of 20/200 in the remaining eye with the other eye enucleated yields approximately 60% under the combined tables. |
| 30% | Post-treatment residuals with moderate visual impairment. Visual acuity in the affected eye of 20/100 or the combination of both eyes at lower impairment levels per Tables I-VI. Significant scotomas, concentric visual field constriction to 31-40 degrees, or moderate secondary complications such as controlled glaucoma with mild visual impact may yield ratings in this range. |
CFR: Combined rating tables under 38 CFR 4.79 determine exact percentage based on both eyes. A 30% rating typically results from combined visual acuity of one eye at 20/100 paired with the other eye near normal, or moderate field defects in both eyes. Scotoma affecting at least 1/4 of the visual field is rated as a reduced acuity level. |
| 10% | Post-treatment residuals with mild visual impairment. Best-corrected visual acuity near normal (e.g., 20/40 to 20/70 in the affected eye) with minimal field defects, well-controlled secondary conditions, or minor symptomatic complaints. This level applies when the primary cancer has been treated and residual functional impairment is mild. |
CFR: A 10% rating results from combined table entries where both eyes have near-normal or mildly impaired vision. Residual symptoms that are present but not functionally limiting may support a minimum compensable rating under 38 CFR 4.79. |
100% Active malignant neoplasm of the eyeball, OR surgery more ex ...
Active malignant neoplasm of the eyeball, OR surgery more extensive than enucleation performed (e.g., orbital exenteration), rated as 100% during the period of active treatment and for a minimum of 6 months following the completion of treatment. After the treatment period, the condition is rated based on residual conditions under the appropriate diagnostic codes.
Key Symptoms
- Active tumor with ongoing treatment (chemotherapy, radiation, immunotherapy, plaque brachytherapy)
- Surgery more extensive than enucleation such as orbital exenteration
- Active disease confirmed by imaging or biopsy
- Metastatic spread from primary ocular malignancy
- Severe functional impairment from active disease
CFR: Under DC 6014, malignant neoplasm of the eyeball is rated 100% while active and for 6 months following completion of treatment. Post-treatment residuals are then rated under the applicable diagnostic codes for visual impairment, field defects, or other residual conditions. A mandatory VA examination is required no later than the end of the 6-month period after completion of treatment.
60% Post-treatment residual rating based on visual acuity in the ...
Post-treatment residual rating based on visual acuity in the remaining eye(s). If the affected eye has been enucleated (removed), the remaining eye's best-corrected visual acuity combined with any visual field defects determines the rating under Tables I-VI of 38 CFR 4.79. Visual acuity of 20/200 or worse in the remaining eye after enucleation of the other eye typically yields a 60% or higher combined rating.
Key Symptoms
- Enucleation of one eye with significant visual impairment in the remaining eye
- Best-corrected visual acuity 20/100 to 20/200 in the remaining eye
- Significant visual field constriction (21-30 degrees remaining)
- Secondary glaucoma with moderate vision loss
- Radiation-induced cataract with moderate visual impairment
- Retinal detachment residual with moderate visual loss
CFR: Under Tables I-VI, various combinations of visual acuity in both eyes yield specific combined ratings. After enucleation of one eye, the rating is determined by the remaining eye's acuity. Visual acuity of 20/200 in the remaining eye with the other eye enucleated yields approximately 60% under the combined tables.
30% Post-treatment residuals with moderate visual impairment. Vi ...
Post-treatment residuals with moderate visual impairment. Visual acuity in the affected eye of 20/100 or the combination of both eyes at lower impairment levels per Tables I-VI. Significant scotomas, concentric visual field constriction to 31-40 degrees, or moderate secondary complications such as controlled glaucoma with mild visual impact may yield ratings in this range.
Key Symptoms
- Visual acuity 20/100 in the affected eye post-treatment
- Concentric visual field constriction 31-40 degrees
- Scotoma affecting a significant portion of the central or peripheral field
- Secondary glaucoma controlled with medications
- Radiation cataract with mild-to-moderate visual blur
- Photophobia requiring tinted lenses
- Mild diplopia in extreme gaze positions
CFR: Combined rating tables under 38 CFR 4.79 determine exact percentage based on both eyes. A 30% rating typically results from combined visual acuity of one eye at 20/100 paired with the other eye near normal, or moderate field defects in both eyes. Scotoma affecting at least 1/4 of the visual field is rated as a reduced acuity level.
10% Post-treatment residuals with mild visual impairment. Best-c ...
Post-treatment residuals with mild visual impairment. Best-corrected visual acuity near normal (e.g., 20/40 to 20/70 in the affected eye) with minimal field defects, well-controlled secondary conditions, or minor symptomatic complaints. This level applies when the primary cancer has been treated and residual functional impairment is mild.
Key Symptoms
- Visual acuity 20/40 to 20/70 in the treated eye
- Minimal or no visual field defects
- Mild dry eye from radiation with adequate treatment response
- Minor photophobia or glare sensitivity
- Mild eyelid changes (partial lash or brow loss) without functional impact
- Prosthetic eye fitting with good cosmetic result and no socket complications
CFR: A 10% rating results from combined table entries where both eyes have near-normal or mildly impaired vision. Residual symptoms that are present but not functionally limiting may support a minimum compensable rating under 38 CFR 4.79.
How to Describe Your Symptoms
Visual Acuity Loss
How to describe:
Describe exactly what you can and cannot see at various distances. Use specific functional examples: 'I cannot read a newspaper even with my glasses,' 'I cannot recognize my family members' faces across the room,' 'I cannot safely drive even with correction,' 'I struggle to read street signs.' Be specific about which eye is affected and whether the other eye compensates.
Worst-day example:
“On my worst days, my vision in the affected eye is so blurred that I see only shapes and light even with my glasses on. I cannot read anything up close, I bump into objects on my left side because I have no usable vision there, and I have completely stopped driving because I cannot judge distances safely.”
What the examiner listens for:
Specific functional limitations, whether vision fluctuates, whether the loss is stable or progressive, whether correction helps or does not help, and how it impacts ADLs and employment.
Understatements to avoid:
Do not say 'my vision is okay with glasses' if it is not. Do not minimize difficulty reading or driving. Do not say 'I manage fine' when you have significantly altered your life to accommodate the vision loss.
Ocular Pain and Discomfort
How to describe:
Describe the character (aching, stabbing, burning, pressure), frequency (constant, episodic, daily), severity (rate 1-10 on your worst days), location (in the eye socket, behind the eye, forehead, temporal area), and what makes it better or worse (light, eye movement, dry conditions, reading). Distinguish between phantom pain in an enucleated socket versus pain in a remaining eye.
Worst-day example:
“On my worst days, I have a constant burning and aching pain in my eye socket that I rate 7 out of 10. The pain prevents me from concentrating at work, disturbs my sleep, and is not fully controlled by my current medications. Looking at bright light or computer screens makes it significantly worse.”
What the examiner listens for:
Frequency of incapacitating episodes, whether pain prevents normal activity, whether prescribed medications are needed, duration of episodes, and whether pain is a new or worsening symptom.
Understatements to avoid:
Do not describe only your average pain - describe your worst typical day. Do not omit phantom eye pain after enucleation, as this is a legitimate and ratable symptom. Do not say pain is 'tolerable' if it limits your activities.
Visual Field Defects and Scotomas
How to describe:
Describe what areas of your vision are missing or dark. Use concrete examples: 'There is a dark spot in the center of my vision that blocks my ability to read,' 'I cannot see anything to my left without turning my head,' 'I have a missing area in the lower left of my vision that causes me to miss steps on stairs,' 'I have to turn my head fully to see what others see with a glance.'
Worst-day example:
“My central vision has a large dark area that makes reading impossible without magnification. I frequently misjudge the edges of doorways and have walked into objects on my left side. I cannot see a full page of text without moving my eyes and head extensively. Driving at night is impossible because I miss objects in my peripheral field entirely.”
What the examiner listens for:
The functional impact of field loss, whether it is getting worse, specific gaze directions affected, and how field loss impacts safety (driving, walking, occupational tasks).
Understatements to avoid:
Do not skip mentioning field defects because you have adapted to them - adaptation does not mean the defect is absent. Do not describe only the most obvious field loss; mention all areas of reduced or absent vision.
Photophobia and Glare Sensitivity
How to describe:
Describe how light sensitivity affects your daily life. Specify triggers (sunlight, fluorescent lights, headlights at night, computer screens), how long exposure causes symptoms, whether you need to wear sunglasses indoors or use blackout curtains, and whether it limits your ability to work or perform activities.
Worst-day example:
“On bright sunny days or under fluorescent office lighting, I experience such severe light sensitivity that my eye tears up uncontrollably and I cannot keep it open. I wear sunglasses even indoors and have had to decline social and work activities in brightly lit environments. Driving at night is impossible because oncoming headlights cause temporary visual incapacitation.”
What the examiner listens for:
Whether photophobia is severe enough to cause incapacitating episodes, whether adaptive measures (tinted lenses, dark environments) are necessary for functioning, and whether it is a new or worsening symptom.
Understatements to avoid:
Do not dismiss photophobia as a minor nuisance if it significantly limits your activities. Be specific about what activities you have stopped or reduced because of light sensitivity.
Treatment Side Effects and Residual Complications
How to describe:
Describe all side effects from cancer treatment that persist to today: radiation-induced dry eye (burning, foreign body sensation, discharge, need for frequent artificial tears), radiation cataract (progressive blurring, haze), secondary glaucoma (pressure symptoms, need for drops), eyelid changes, prosthesis-related socket discomfort, and any systemic chemotherapy side effects that affect the eye.
Worst-day example:
“Since completing radiation therapy, my eye is constantly dry, burning, and feels like there is sand in it. I use artificial tears 8-10 times per day and still have significant discomfort. I wake up with my eye crusted shut and need several minutes to open it. The dryness has made reading and computer work almost impossible for more than 15-20 minutes at a stretch.”
What the examiner listens for:
Which treatments were received and their completion dates, which side effects are current and ongoing, frequency of symptom management interventions, and whether side effects are worsening or stable.
Understatements to avoid:
Do not assume the examiner knows about your radiation or surgical history - volunteer this information clearly. Do not omit side effects you consider 'expected' from cancer treatment, as they are all potentially ratable.
Incapacitating Episodes
How to describe:
An incapacitating episode for ocular conditions is one that requires a physician's prescription treatment or that prevents you from performing your usual daily activities. Describe episodes of acute pain, sudden vision loss, pressure spikes (glaucoma), severe photophobia, or socket infections that require urgent medical care or rest. Document frequency (how many per month or year) and duration (how many days each).
Worst-day example:
“Approximately twice per month, my eye pain and light sensitivity become so severe that I cannot go to work and must rest in a darkened room. Each episode lasts 1-3 days. During these episodes, my doctor has prescribed additional pain medications and eye drops beyond my usual regimen. Over the past year, these episodes have caused me to miss at least 20 days of work.”
What the examiner listens for:
Frequency and duration of episodes, whether medical care was sought, prescription medications required during episodes, and functional impairment during episodes.
Understatements to avoid:
Do not fail to mention incapacitating episodes because they seem infrequent to you. Even 1-2 per month is highly significant for rating purposes. Do not fail to mention time lost from work or daily activities during these episodes.
Common Mistakes to Avoid
Failing to mention all cancer treatment modalities received
The DBQ has specific fields for surgery type (enucleation vs. more extensive), radiation therapy, chemotherapy, and immunotherapy. Missing any treatment type may result in an incomplete rating picture.
Instead: Prepare a written list of every treatment received including dates, facility, and the name of the treating oncologist/ophthalmologist. Bring copies of pathology reports, radiation records, and surgical operative notes.
Impact: 100% during active treatment period; post-treatment residual rating
Not clearly stating the cancer is currently active versus in remission or cured
Active malignancy triggers an automatic 100% rating under DC 6014. If the examiner incorrectly documents the condition as resolved when it is still active or under watchful waiting, the rating will be incorrectly reduced.
Instead: Bring current oncology records showing your cancer status. If you are in 'watchful waiting,' active surveillance, or recently completed treatment within 6 months, clearly state this. Bring documentation of your most recent oncology visit.
Impact: 100% active; transition to residual rating
Describing only average vision, not worst-day vision
VA rating is meant to capture the disabling impact of a condition, and M21-1 guidance supports evaluating the condition at its worst typical presentation. Describing only 'good days' results in an underrated disability picture.
Instead: When asked how your vision is, describe your worst typical day explicitly. Say: 'On my worst days, which happen [frequency], my vision is [description].' Also describe your average days and best days separately so the examiner has a complete picture.
Impact: All rating levels
Failing to report secondary conditions caused by the cancer or its treatment
Secondary glaucoma, radiation cataract, retinal detachment, optic neuropathy, dry eye syndrome, and eyelid deformities are all separately ratable conditions that can increase the overall combined rating significantly.
Instead: File separate claims for all secondary conditions at the same time as or immediately after your primary cancer claim. At the exam, volunteer information about each secondary condition even if not directly asked. The DBQ has specific sections for each of these.
Impact: All rating levels; combined rating impact
Minimizing pain or saying 'it's not that bad' to the examiner
Pain severity directly affects the rating for ocular conditions and also supports claims for incapacitating episodes. Underreporting pain leads to lower ratings.
Instead: Rate your pain on a numeric scale (1-10) and always describe your worst typical pain level, not just the pain you feel at the moment of the exam. Describe how pain limits your activities, sleep, work, and social functioning.
Impact: All residual rating levels
Not requesting that the examiner document an ocular prosthesis or anophthalmic socket
If you had the eye removed, the examiner must specifically document this for proper coding. Enucleation is rated differently from more extensive surgery, and both affect the rating significantly. If this is not in the DBQ, the rating may be incorrect.
Instead: If you have a prosthetic eye or your eye was removed, state this clearly at the start of the exam. Bring surgical records showing the type of surgery performed (enucleation vs. evisceration vs. exenteration).
Impact: 100% for extensive surgery; significant residual rating
Forgetting to disclose diplopia or double vision
Diplopia is a separately ratable symptom under the DBQ and under the visual impairment tables. Even occasional diplopia in certain gaze positions is ratable and can increase the combined rating.
Instead: Tell the examiner whether you experience double vision, in which directions of gaze, whether it is constant or intermittent, and whether you use prism glasses to manage it. Document the functional impact (inability to drive, read, watch screens).
Impact: Residual rating levels; may affect combined rating
Arriving at the exam without relevant records
The examiner's DBQ specifically asks for treatment history, dates of procedures, medication names, and residual condition descriptions. Without records, the examiner relies solely on your verbal history, which may be incomplete and can result in a less favorable nexus opinion.
Instead: Bring: oncology and ophthalmology treatment records, surgical operative reports, radiation therapy records, pathology/biopsy reports, most recent imaging (MRI/CT/ultrasound of orbit), current medication list, and any prior VA rating decisions.
Impact: All levels; nexus and rating accuracy
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to a C&P examination conducted by a qualified ophthalmologist or optometrist. If your examination is conducted by an unqualified examiner, you may request a new examination through a supplemental claim.
- You have the right to request a copy of the completed DBQ form following your examination through a records request via VA.gov or your regional office.
- You have the right to record your C&P examination in most states. Check your state's recording consent laws and notify the examiner at the start of the exam if you choose to record.
- You have the right to submit a written statement or additional evidence to supplement or correct the DBQ findings after the exam. This can be submitted to your regional office or through a supplemental claim.
- Under 38 CFR 3.159, VA has a duty to assist you in developing your claim, including ordering an adequate examination. An examination that is inadequate (not conducted by a specialist, fails to address all conditions, or contains clear errors) can be challenged.
- Active malignant neoplasm entitles you to an automatic 100% rating during the treatment period and for 6 months after completion of treatment, after which a mandatory reexamination must be scheduled. You have the right to ensure this mandatory exam is scheduled per 38 CFR 3.105.
- You have the right to have all secondary conditions caused by your eye cancer or its treatment evaluated and rated separately. Secondary glaucoma, radiation cataract, retinal detachment, optic neuropathy, and dry eye syndrome are all potentially separately ratable conditions.
- If you are 100% rated for active malignancy or have significant vision loss, you may be entitled to Special Monthly Compensation (SMC) under 38 USC 1114. Ask your VSO or claims agent to evaluate your eligibility for SMC-K (loss of use of a creative organ) or SMC-L and above for loss of use of an extremity-equivalent organ.
- You have the right to a free Veteran Service Officer (VSO) to assist with your claim at no cost. VSOs can attend your C&P exam with you, help you prepare a personal statement, review your DBQ for errors, and file supplemental claims if the exam was inadequate.
- You have the right to an IMO (Independent Medical Opinion) from a private ophthalmologist. A private IMO that provides a well-reasoned nexus opinion and documents the full extent of your residual conditions can significantly strengthen your claim, particularly for secondary conditions.
Related Conditions
- Secondary Glaucoma (Neovascular or Radiation-Induced) Common secondary condition following treatment for ocular malignancy, particularly after radiation therapy (plaque brachytherapy or external beam) or following enucleation. Elevated IOP from neovascularization, trabecular damage, or steroid response is separately ratable under DC 6012.
- Radiation-Induced Cataract A well documented complication of radiation therapy to the eye, typically developing months to years after treatment. Posterior subcapsular cataracts are characteristic of radiation exposure. Separately ratable under DC 7000 as a lens condition caused by service connected cancer treatment.
- Retinal Detachment Can occur secondary to radiation treatment, tumor related traction, or surgical complications. Separately ratable under DC 6006 and can significantly reduce visual acuity and field, impacting the overall combined rating.
- Optic Neuropathy (Radiation-Induced) Radiation optic neuropathy is a delayed complication of external beam radiation or proton therapy for ocular tumors, causing progressive vision loss. Separately ratable under DC 6090 for optic nerve conditions.
- Dry Eye Syndrome (Keratoconjunctivitis Sicca) Radiation therapy damages lacrimal glands and goblet cells, causing chronic dry eye syndrome. This is a common, significant, and separately ratable condition (DC 6025) that causes pain, photophobia, and visual disturbance.
- Ptosis Drooping of the upper eyelid can occur following orbital surgery, radiation, or tumor infiltration of the levator muscle or its nerve supply. Separately ratable and can impair functional visual field by obstructing the superior visual field.
- Diplopia (Double Vision) Extraocular muscle involvement by tumor, radiation fibrosis of orbital tissues, or cranial nerve damage from tumor spread can cause persistent diplopia. Separately ratable and can significantly impair function and employment.
- Loss of Use of Eye (SMC Consideration) If the malignancy results in no light perception or loss of the eye itself (enucleation), the veteran may qualify for Special Monthly Compensation (SMC K or higher) in addition to the schedular rating for visual impairment. This should be specifically evaluated when vision in the affected eye is absent.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.